Antonio Pérez Martínez-rekin lankidetzan egindako argitalpenak (8)

2024

  1. Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210)

    Cytotherapy, Vol. 26, Núm. 1, pp. 25-35

2023

  1. Rationale for combined therapies in severe-to-critical COVID-19 patients

    Frontiers in Immunology, Vol. 14

  2. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

    Bone Marrow Transplantation

2022

  1. Identifying SARS-CoV-2 ‘memory’ NK cells from COVID-19 convalescent donors for adoptive cell therapy

    Immunology, Vol. 165, Núm. 2, pp. 234-249

2021

  1. A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol

    Trials, Vol. 22, Núm. 1

  2. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)

    EClinicalMedicine, Vol. 39

  3. SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy

    Frontiers in Cell and Developmental Biology, Vol. 9

  4. The race of CAR therapies: CAR-NK cells for fighting B-cell hematological cancers

    Cancers, Vol. 13, Núm. 21